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Background: CXCL1 is a chemotactic cytokine shown to regulate breast cancer progression and chemo-resistance.
However, the prognostic significance of CXCL1 expression in breast cancer has not been fully characterized. Fibroblasts
are important cellular components of the breast tumor microenvironment, and recent studies indicate that this cell
type is a potential source of CXCL1 expression in breast tumors. The goal of this study was to further characterize the
expression patterns of CXCL1 in breast cancer stroma, determine the prognostic significance of stromal CXCL1
expression, and identify factors affecting stromal CXCL1 expression.
Methods: Stromal CXCL1 protein expression was analyzed in 54 normal and 83 breast carcinomas by
immunohistochemistry staining. RNA expression of CXCL1 in breast cancer stroma was analyzed through data
mining in www.Oncomine.org. The relationships between CXCL1 expression and prognostic factors were analyzed by
univariate analysis. Co-immunofluorescence staining for CXCL1, α-Smooth Muscle Actin (α-SMA) and Fibroblast Specific
Protein 1 (FSP1) expression was performed to analyze expression of CXCL1 in fibroblasts. By candidate
profiling, the TGF-β signaling pathway was identified as a regulator of CXCL1 expression in fibroblasts. Expression
of TGF-β and SMAD gene products were analyzed by immunohistochemistry and data mining analysis. The relationships
between stromal CXCL1 and TGF-β signaling components were analyzed by univariate analysis. Carcinoma associated
fibroblasts isolated from MMTV-PyVmT mammary tumors were treated with recombinant TGF-β and analyzed for CXCL1
promoter activity by luciferase assay, and protein secretion by ELISA.
Results: Elevated CXCL1 expression in breast cancer stroma correlated with tumor grade, disease recurrence and
decreased patient survival. By co-immunofluorescence staining, CXCL1 expression overlapped with expression of α-SMA
and FSP1 proteins. Expression of stromal CXCL1 protein expression inversely correlated with expression of TGF-β signaling
components. Treatment of fibroblasts with TGF-β suppressed CXCL1 secretion and promoter activity.
Conclusions: Increased CXCL1 expression in breast cancer stroma correlates with poor patient prognosis. Furthermore,
CXCL1 expression is localized to α-SMA and FSP1 positive fibroblasts, and is negatively regulated by TGF-β signaling.
These studies indicate that decreased TGF-β signaling in carcinoma associated fibroblasts enhances CXCL1 expression in
fibroblasts, which could contribute to breast cancer progression.
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Breast cancer remains the most common form of cancer
diagnosed in women in the US and the world, with over
1.3 million new cases annually [1,2]. 80% of all invasive
breast cancers in the US are diagnosed as invasive ductal
carcinoma (IDC). Current treatments for IDC include
radiation, chemotherapy, hormone therapy and targeted
HER2 therapy [3-5]. Yet, up to 56% of patients with stage
III breast cancer still experience disease recurrence. Disease
recurrence for patients with late stage breast cancer is often
accompanied by distant metastasis, contributing to an 80%
mortality rate [6,7]. Treatment effectiveness is complicated
by the presence of reactive stroma, which is associated with
tumor invasiveness and drug resistance [8-11]. In order to
tailor treatments more effectively to the individual patient,
it is important to define clearly the breast tumor
stroma at a molecular level, which will enable us to
identify biomarkers that will more accurately predict
patient responsiveness to treatments.
Fibroblasts are a key cellular component in breast
stroma, normally activated during mammary gland
development to regulate ductal branching and morpho-
genesis [12,13]. De-regulation of fibroblast growth and
activity is associated with breast cancer. Carcinoma-
associated fibroblasts (CAFs) are commonly identified
by their spindle cell morphology and expression of
mesenchymal markers including Fibroblast Specific
Protein 1 (FSP1), alpha Smooth Muscle Actin (α − SMA),
and Fibroblast Activating Protein (FAP) [14,15]. Accu-
mulation of CAFs strongly correlates with tumor grade
and poor patient prognosis [16-18]. Co-transplantation
studies and transgenic mouse studies have demonstrated
that CAFs enhance breast tumor growth and invasion
[19-21]. Conversely, co-transplantation of normal fibro-
blasts with breast cancer cells inhibits cellular invasive-
ness and inhibits tumor progression [22]. These studies
indicate that fibroblasts may enhance or inhibit breast
cancer progression dependent on the tissue of origin.
Recent studies demonstrate the importance of CAFs in
chemo-resistance. Fibroblasts are more resistant to
chemotherapy than cancer cells, including melanoma and
squamous cell carcinoma [23]. In animal models,
Doxorubicin treatment results in increased CAF secretion
of growth factors and cytokines involved in the develop-
ment of drug resistant prostate and colorectal cancers
[24,25]. Targeting FAP expressing CAFs in animal models
has been shown to inhibit growth of invasive tumors and
enhance chemo-sensitivity to Doxorubicin in colon and
breast cancers [26,27]. Yet, the use of FAP inhibitors has
not been successful in clinical trials [28,29]. This result may
be due in part to the complex identity of CAFs. Fibroblasts
are not a uniform population of cells. One type of
CAF in breast cancer is the myofibroblast, which expresses
α − SMA [30,31]. Another type of breast CAF expressesFSP1 but not α − SMA [32]. Furthermore, fibroblasts may
be derived from different origins including embryonic
mesenchyme, endothelial cells, macrophages and cancer
cells [15]. These studies indicate the presence of different
populations of CAFs. Currently, the molecular signals
that identify tumor-promoting fibroblasts remain poorly
understood.
Emerging studies indicate an important clinical signifi-
cance for chemokine expression in cancer stroma.
Chemokines are a family of small soluble proteins
(8-10 kda) that regulate angiogenesis and immune cell
recruitment during inflammation and cancer [33-35].
Chemokines bind to seven transmembrane spanning
receptors which couple to G proteins and activate
signaling pathways involved with cell migration and
differentiation. As a large family of molecules, chemokines
are categorized into distinct families: C, C-C, C-X-C, and
CX3C, in which a conserved cysteine motif may also
include an amino acid (X) in their NH2 terminal domain.
The C-X-C chemokine family is currently comprised
of 17 ligands, which bind promiscuously to 7 chemokine
receptors (CXCR1-7). A conserved glutamic acid-leucine-
arginine (ELR) motif has been detected in a small
subset of C-X-C chemokines (CXCL1, 2, 3, 5, 8), which is
important for stimulating angiogenesis and regulating
recruitment of neutrophils [36,37]. Up-regulated expression
of ELR positive chemokines have been detected in various
cancers, associated with increased angiogenesis and
immune cell recruitment. CXCL3 is up-regulated in
prostate cancer [38] while CXCL5 has been detected in
lung and liver cancers [39]. Increased expression of CXCL1
has been reported in multiple tumor types including
prostate cancer, gastric cancer, renal cell carcinoma and
melanoma [40,41]. These studies indicate aberrant
expression of C-X-C chemokines in cancer.
Recent reports have implicated a role for CXCL1 in
breast cancer. Increased CXCL1 protein expression was
associated with increased tumor growth and pulmonary
metastasis of MDA-MB-231 breast cancer cells grafted
in the mammary fat pads of nude mice [42]. Increased
CXCL1 protein expression has been reported in HER2
positive metastatic breast cancer [43]. Increased plasma
levels of CXCL1 protein are associated with decreased
survival of patients with metastatic disease [44]. Similarly,
increased tumoral expression of CXCL1 RNA is associated
with metastatic disease, correlating with tumor grade and
decreased survival of patients with ER-α positive
breast cancer [45]. These studies demonstrate a clinical
significance for CXCL1 expression in breast cancer.
Previous studies have reported positive RNA expression
of CXCL1, CXCL3, CXCL5, CXCL6 and CXCL8 in stromal
cells including: blood-circulating cells, fibroblasts and endo-
thelial cells [45]. These studies indicate that expression of
binding ligands to CXCR2 is not restricted to epithelial
Table 1 Characteristics of breast ductal carcinoma
samples from US Biomax and the BRCF core combined
Prognostic factor No. of DCIS cases
(percentage of total)
No. of IDC cases
(percentage of total)
Histologic grade
1 2 (9%) 10 (18%)
2 7 (32%) 24 (41%)
3 12 (59%) 24 (41%)
Tumor size
>2 cm 16 (70%) 10 (36%)
<2cm 7 (30%) 18 (64%)
BCL2
negative 4 (27%) 8 (42%)
positive 11 (73%) 11 (57%)
P53
negative 7 (38%) 9 (36%)
positive 11 (62%) 16 (64%)
Ki67
>50% 3 (16%) 5 (22%)
<50% 16 (84%) 18 (78%)
ER
negative 7 (38%) 9 (36%)
positive 11 (62%) 16 (64%)
PR
negative 7 (38%) 11 (47%)
positive 11 (62%) 13 (53%)
HER2
negative 0 7 (32%)
positive 18 (100%) 15 (68%)
EGFR
negative 7 (38%) 10 (50%)
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examine the prognostic significance of RNA expression of
CXCR2 binding ligands in the breast cancer stroma, or
examine their protein expression patterns in the
stroma. Biomarker expression patterns in the stroma
and epithelium can have vastly different relationships
to known prognostic factors and clinical outcomes
[46]. Given the importance of CXCL1 expression in breast
cancer, the goal of this study was to: characterize further
the expression patterns of CXCL1 in breast cancer stroma,
determine the prognostic significance of stromal CXCL1
expression and identify factors affecting stromal CXCL1
expression. We used a combination of data-mining
analysis and immunohistochemistry staining of patient
samples to investigate the RNA and protein expression
patterns of CXCL1 in the breast stroma. Our studies
indicated that patient samples expressed high levels of
CXCL1 RNA and protein in breast cancer stroma,
correlating with tumor grade. CXCL1 RNA expression
levels were significantly associated with tumor recurrence
and decreased patient survival. CXCL1 protein expression
co-localized to FSP1 and α-SMA positive cells, indicating
that CXCL1 is expressed in more than one population
of CAFs. Increased CXCL1 in CAFs correlated with
decreased TGF-β expression. Immunostaining analysis of
breast tumor tissues indicated that increased CXCL1
expression inversely correlated with expression of TGF-β,
phospho-SMAD2 and phospho-SMAD3. Treatment of
cultured CAFs with TGF-β suppressed CXCL1 secretion
and promoter activity. In summary, these studies indicate
a prognostic significance for CXCL1 expression in
breast cancer stroma, show that CXCL1 is localized to
multiple fibroblast populations, and is negatively regulated
by TGF-β signaling.
Methods
Patient samples used for immunohistochemistry analysis
Samples were collected from commercial (US Biomax Inc)
and institutional resources from the University of Kansas
Medical Center. Characteristics of patients from both data-
sets are summarized (Table 1). When the datasets were
combined, the median age of normal patients was 48.6 years,
51 years for DCIS patients and 50.5 years for IDC patients.
US biomax samples
Tissue microarrays (TMA) containing de-identified cores
of 18 normal and 26 invasive breast ductal carcinoma
samples were obtained from US Biomax (cat. nos. 8032
and 241). Normal breast tissue samples came from
adjacent tissues of breast cancer patients. The breast
samples were collected from patients originating in
South Korea and China. Normal women had a median
age of 43 years and women with IDC had a median age of
44.6 years.Biospecimen Repository Core Facility (BCRF)
Patient samples of normal, Ductal Carcinoma In Situ
(DCIS) and IDC were obtained from the BRCF, an IRB
approved facility at the University of Kansas Medical
Center. Out of the 36 normal samples collected from the
BCRF, 13 samples were collected from adjacent tissues
of breast cancer patients, and 23 samples were collected
from patients undergoing reduction mammoplasty. Tumor
samples were collected from Caucasian women who were
diagnosed with primary breast ductal carcinoma, and had
not been treated with radiation or chemotherapy before
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specimens were obtained as individual paraffin blocks.
Tissue microarrays were generated from an additional
22 normal, 20 DCIS and 14 IDC specimens. Normal
women had a median age of 51.5 years and women
with IDC had a median age of 51 years.
Pathology reports included information on clinical
diagnosis, and information on tumor grade, tumor size,
lymph node status, biomarker expression and age. DCIS
samples were graded according to the Van Nuys System.
IDC samples were graded according to the Scarff-Bloom
and Richardson system. Intensity of staining or percentage
of positive cells were reported for BCL2, p53, ER, PR, Her2
and EGFR biomarkers, and are summarized as positive or
negative. As the samples were collected within the last
4 years, no follow-up data was available. Prognostic factor
data that was present in more than 55% of the pathology
reports were reported. Tumor grade and age were
combined from both US Biomax and the BCRF (Table 1).
Immunohistochemistry staining
CXCL1 protein expression was examined on patient
samples obtained from US Biomax and the BRCF
core. Expression of TGF-β, phospho-SMAD2 and
phospho-SMAD3 proteins was primarily analyzed on
patient samples obtained from the BRCF core. Tissue
sections (5 microns) were de-waxed and rehydrated in
PBS. Sections were subjected to antigen retrieval in
10 mM sodium citrate buffer pH 6.0 for 10 minutes
at 100°C and washed in PBS. Endogenous peroxidases
were quenched in PBS containing 3% H202 and 10%
methanol for 30 minutes. After rinsing in PBS, samples
were blocked in PBS containing 5% rabbit serum and
incubated with antibodies (1:100) to CXCL1 (cat. no. 1374,
Santa Cruz Biotechnology), TGF-β (cat. no. MAB 240,
R&D Systems), phospho-SMAD2 (Ser465/467) (cat. no.
3101, Cell Signaling Technologies), or phospho-SMAD3
(Ser 423/425) (cat. no. C25A9, Cell Signaling Technologies)
overnight at 4°C. Samples were washed in PBS and
incubated with secondary goat biotinylated antibodies
(1:500) (cat. no. BA-5000, Vector Labs), conjugated
with streptavidin peroxidase (cat. no. PK-4000, Vector
Labs) and incubated with 3,3′-Diaminobenzidine (DAB)
substrate (cat. no. K346711, Dako). Sections were counter-
stained with Harris’s hematoxylin for 5 minutes, dehydrated
and mounted with Cytoseal.
Quantification of immunohistochemistry staining
Immunohistochemistry staining was imaged at 10× magni-
fication using a Motic AE 31 microscope with Infinity 2-1c
color digital camera. Four fields were captured for each at
10× magnification. To analyze biomarker expression in
stromal tissues, we adapted methods described in previous
studies [47-49]. Images were first imported into AdobePhotoshop. Hue and saturation of images were normalized
using Auto-Contrast. Tumor epithelium was distinguished
from stroma by differences in nuclear and cellular
morphology, and tissue architecture. Using the lasso
tool, epithelial tissues were selected and cropped out
from the image, leaving the stromal tissues behind.
These stromal tissues were labeled as “total stromal
area.” DAB chromogen staining (brown) was selected
using the Magic Wand Tool in the Color Range Window,
with a specificity range of 66. The selected pixels were
copied and pasted into a new window and saved as a
separate file. DAB positive images were opened in
Image J and converted to greyscale. Background pixels
resulting from luminosity of bright-field images were
removed by threshold analysis. Images were then subject
to particle analysis. Positive DAB staining and total
stromal areas were expressed as particle area values
of arbitrary units. Positive DAB values were normalized to
total stromal values.
Immunofluorescence staining
Normal or breast cancer sections were de-paraffinized and
treated with sodium citrate as described for immunohisto-
chemistry. Sections were permeabilized in PBS containing
10% Methanol for 30 minutes, washed in PBS and blocked
for 1 hour with PBS containing 3% fetal bovine
serum. Mouse IgGs were blocked using the M.O.M kit
(cat. no. BMK-2202, Vector Labs) according to commercial
protocol. For co-immunofluorescence staining of CXCL1
and FSP1, sections were incubated with goat polyclonal
antibodies to CXCL1 at a 1:100 dilution (cat. no. 1374,
Santa Cruz Biotechnology), and with rabbit polyclonal
antibodies to FSP1 (pre-diluted solution cat. no. 27597,
Abcam) in PBS/3% FBS overnight. For co-staining of
CXCL1 and α-SMA, sections were incubated with
antibodies overnight at 4°C, to CXCL1 at a 1:100
dilution, and mouse monoclonal antibodies to α-SMA at a
1:100 dilution (cat. no. ab134813, Abcam). Sections were
then washed in PBS and incubated with the following
secondary antibodies at a 1:500 dilution in blocking
buffer for 1 hour: anti-goat-alexa-488 to detect CXCL1
expression, anti-mouse-alexa-568 to detect α-SMA, or
anti-rabbit-alexa-488 to detect FSP1 expression. Sections
were washed in PBS and countered with DAPI. Slides
were mounted in Anti-Fade (cat. no. P36935, Invitrogen).
Fluorescence images were taken at 20× magnification
using the Motic AE-31 microscope.
RNA expression analysis
RNA expression values in breast stromal samples were
obtained from the microarray database in www.Oncomine.
org, characterized by Finak et al. in previous studies [9,50].
Briefly, tissue samples were collected from 53 patients with
invasive breast carcinoma, of which 50 were diagnosed as
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micro-dissection and hybridized to microarrays. Six normal
samples were obtained from adjacent tissues of breast
cancer patients. Patient samples included follow-up data,
including information on recurrence and poor survival
outcome. With a 5 year follow-up, 8 patients exhibited no
recurrence and 11 patients exhibited recurrence. There
were no data on the remaining 34 patients with IDC. Poor
survival outcome was defined as patients who died from
disease at the time of follow-up. 43 patients were alive
without disease, 4 patients were alive with disease, 3
patients died of disease and 1 patient died of other causes.
The Finak database provided as Log2 median RNA expres-
sion values and prognostic information, including age,
tumor grade and tumor size. The database did not include
information on which cases were invasive lobular carcinoma,
and were therefore included in the analysis.
Cell culture
Primary mammary carcinoma-associated fibroblasts (CAFs)
were isolated from MMTV-PyVmT transgenic mice [51] at
12-16 weeks of age. Primary normal mammary tissue
associated fibroblasts (NAFs) were isolated from wild-type
C57/BL6 mice at 12-16 weeks of age. FspKO fibroblasts
were isolated from FspKO knockout mice as described
[49]. Fibroblast cell lines were generated by spontaneous
immortalization of primary mammary fibroblasts, as
described [49]. Primary human fibroblasts were isolated
from patient samples from reduction mammoplasty or
invasive ductal carcinoma from the BRCF, using methods
described [52]. Primary cells were cultured on 10-cm
dishes coated with rat tail collagen I. All cells were
cultured in Dulbecco’s modified Eagle medium (DMEM)
containing 10% fetal bovine serum (FBS) (cat. no. FR-0500-A,
Atlas Biological), 2 mM L-glutamine (cat. no. 25-005-CI,
Cellgro) and 100 I.U/ml of penicillin/100 μg/ml of
streptomycin (cat. no. 10-080, Cellgro).
ELISA
Cells were seeded in a 24-well plate at a density of
20,000 cells for 24 hours. Conditioned medium was
generated by incubating cells in 500 μl Opti-MEM
media for 24 hours, and then centrifuged to eliminate
cell debris. One hundred microliters of conditioned
media, which were generated from indicated cell lines,
were subjected to TGF-β ELISA (cat. no. DY1679, R&D
Systems) or CXCL1 ELISA (cat. no. 250-11, Peprotech).
Samples were analyzed according to manufacturer’s proto-
col. Reactions were catalyzed using a tetramethylbenzidine
substrate (cat. no. 34028, Thermo Scientific) according to
manufacturer’s protocol. The reaction was stopped with
1 M HCl, and absorbance was read at A450nm using a 1420
multi-label plate reader (VICTOR3 TM V, PerkinElmer).
All the samples were analyzed in triplicate.Luciferase assay
Cells were seeded in 6-cm dishes at a density of 150,000
cells for 24 hours, and then co-transfected with 8 μg of
firefly luciferase plasmids (PGL3.luc.CXCL1) and 400 ng
of Renilla luciferase plasmids (plasmid 12177: plS2,
Addgene) using 8.4 μl Lipofectamine LTX and 15 μl Plus
reagents according to manufacturer’s protocol (Invitrogen,
life technologies). After 24 hours, cells were allowed to
recover in Opti-MEM media containing 10% FBS for
24 hours. Cells were re-seeded in a 24-well plate at a
density of 20,000 cells for 24 hours followed by incubation
in serum free Opti-MEM media overnight. Cells were
treated with Opti-MEM media containing 10% FBS in the
presence or absence of 5 ng/ml of TGF-β for 24 hours. Cell
lysates were analyzed using the Dual-Luciferase Reporter
Assay system (cat. no. E1910, Promega) according to manu-
facturer’s instructions. Cells were rinsed twice with PBS,
lysed in 100 μl of passive lysis buffer for 15 min at room
temperature on a shaker. Cell lysates were sonicated for
10 seconds on ice, followed by centrifugation to eliminate
cell debris. Twenty microliters of lysates were assayed in
triplicate in 96 well opaque plates (cat. no. 3912, Corning
Costar) using the Veritas Microplate Luminometer (model
number 9100-202, Turner BioSystems).Ethics and consent statements
The tissues collected for these studies were categorized
under the “Exemption Class,” according to regulations set
forth by the Human Research Protection Program (ethics
committee) at the University of Kansas Medical Center
(#080193). Ethics approval was also obtained from the
Human Research Protection Program at the University of
Kansas Medical Center for the isolation of primary human
fibroblasts from patient biospecimens. Written informed
consent for tissue collection was obtained by the BRCF.
Tissue samples were de-identified by the BRCF prior to
distribution to the investigators. Existing medical records
were used in compliance with the regulations of the
University of Kansas Medical Center. These regulations are
aligned with the World Medical Association Declaration of
Helsinki.
Ethics approval was obtained from the Institutional
Animal Care and Use Committee at the University of
Kansas Medical Center for the isolation of PyVmT
mammary carcinoma cells and fibroblasts.Statistical analysis
In vitro experiments were performed in a minimum of
triplicate. Data are expressed as Mean ± SEM. Statistical
analysis for in vitro experiments was determined using
two-tailed t tests or one way ANOVAs with Bonferonni’s
post-test comparisons in Graphpad Software. Statistical
Significance was determined as p ≤0.05.
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and were observed to be uneven. The uneven sample
populations were due to two factors. Not all prognostic
factors were consistently reported on pathology reports
provided with the biospecimens. In addition, some tissue
samples on tissue microarrays did not adhere to the slide
during staining. Therefore, RNA and protein expression
values and their relationships with prognostic factors
were analyzed using non-parametric methods. Level of
biomarker expression between two groups was analyzed
by Log-rank Test or Wilcoxon two-sample test. Level of
biomarker expression among more than 2 groups was
analyzed by Kruskall-Wallis test with Dunn’s post-hoc
comparison between groups. Spearman rank correlation
was used to analyze the relationship between biomarker
expression and prognostic factors that were expressed as
continuous variables. The Wilcoxon Two-Sample Test
was used to analyze the relationship between biomarker
expression and prognostic factors (such as tumor grade),
which were expressed as discrete variables. Statistical
significance was determined by confidence levels >95%
and p <0.05.
Results
Expression of CXCL1 RNA and protein are elevated in
breast cancer stroma
To determine the significance of CXCL1 expression in
breast stroma, we analyzed the protein and RNA levels of
CXCL1 in breast cancer stroma. Using immunohistochem-
istry approaches, we first analyzed CXCL1 protein expres-
sion patterns in tissues from normal tissues, pre-invasive
lesions known as Ductal Carcinoma in Situ (DCIS) [3,53],
and IDC tissues. CXCL1 protein expression in the stroma
was quantified by software analysis, a method that was
shown to be more reproducible, more consistent and less
biased, compared to manual scoring [47,48]. Consistent
with previous studies [45,54], CXCL1 was expressed
in the tumor epithelium and in the stroma (Figure 1A). By
immunohistochemistry, 87% of normal samples and 100%
of DCIS and IDC samples were positive for CXCL1
protein expression. CXCL1 expression was significantly
higher in DCIS and IDC stroma compared to normal
stroma (Figure 1B). Expression of CXCL1 in IDC stroma
was higher than DCIS stroma; however the difference was
not significant. To determine RNA expression patterns of
stromal CXCL1, we analyzed the microarray dataset
on invasive breast cancer stroma generated by Finak et al.,
which was comprised of 53 cases of invasive breast
carcinoma and 6 cases of normal breast samples [9].
We observed that 33% of normal samples (n =2), and
24% of IDC samples (n =12) were positive for CXCL1
RNA expression (Figure 1C). In the subset of positive
samples, mean intensity of expression in the normal
sample group was 0.19 ± 0.07 (Mean ± SD) comparedto 2.18 ± 1.23 in IDC stroma. Overall, these data indicate
higher intensity of CXCL1 expression in breast cancer
stroma compared to normal breast stroma.
Breast ductal carcinomas often exhibit different
architectural patterns, leading to the classification of
different histological subtypes, which may have prognostic
significance. The comedo subtype is associated with
increased invasiveness, while rarer subtypes including
cribribiform, mucinous and papillary tumors are associated
with a good prognosis [55,56]. In these studies, we
examined for differences in expression of stromal
CXCL1 among the different subtypes of breast cancer.
The majority of tumor samples were classified as ductal
carcinoma- not otherwise specified (NOS), consistent with
the trend of the larger patient population [55]. Additional
samples were classified as mixed solid/cribribiform, solid
or comedo subtype. While stromal CXCL1 was positively
expressed in all groups, there were no significant differ-
ences in expression among the subtypes in either DCIS or
IDC patient samples (Additional file 1: Figure S1 and
Additional file 2: Figure S2). We were unable to draw con-
clusions on mucinous, micropapillary and micropapillary/
solid tumors with only one sample provided in each
group, which reflected the rarity of these subtypes. In
these studies, we can only conclude that CXCL1 is
expressed in the stroma of breast ductal carcinomas of
multiple histologic subtypes.
Associations between stromal CXCL1 expression with risk
factors, prognostic factors and patient outcomes
We first examined for differences between the US
Biomax and BCRF datasets that would potentially
affect stromal CXCL1 expression. In particular, we
examined for associations with age and ethnicity,
which were the risk factors consistently provided by
both datasets. The median age of IDC patients was
46 for the US Biomax dataset, and 51 for the BCRF
dataset. Despite the differences in age, there were no
statistically significant associations between stromal
CXCL1 and age in either dataset, as determined by
Spearman Correlation Analysis (Additional file 3: Table S1).
Samples from US Biomax dataset originated from patients
in South Korea and China while the BCRF samples
came primarily from Causasian women. Despite these
ethnic differences, there were no significant differences in
patterns of stromal CXCL1 between the two datasets
(Additional file 4: Figure S3). These data indicate that
stromal CXCL1 expression is not significantly associated
with age or ethnicity, and that there are no observable
differences in stromal CXCL1 between the two datasets.
We then analyzed for associations between stromal
CXCL1 and established prognostic factors by combining
both datasets. There were no significant associations
between protein expression of CXCL1 among DCIS and
Figure 1 CXCL1 expression is upregulated in the stroma of breast ductal carcinomas. A. CXCL1 expression was analyzed by immunohistochemistry
staining in normal (n =54), DCIS (n =25) or IDC (n =58) tissues. S = Stroma, E = epithelium. Magnified insets show representative CXCL1 staining in stroma.
Scale bar = 50 microns. B. Staining in stroma was quantified by Image J analysis. Statistical analysis was determined by Kruskall-Wallis test with Dunn’s
post-hoc comparison. *p ≤0.001 ***p ≥0.05. Values are expressed as Mean ± SEM. C. CXCL1 RNA expression values were obtained from the Finak microarray
database (Oncomine.org) and analyzed for expression among patient samples.
Zou et al. BMC Cancer 2014, 14:781 Page 7 of 16
http://www.biomedcentral.com/1471-2407/14/781IDC stromal tissues with: tumor size, BCL2 expression,
P53 status, ER, PR, HER2 status, EGFR expression, lymph
node status, Ki67 expression or age, which is also recog-
nized as a prognostic factor [57,58] (Table 2). Increased
stromal CXCL1 protein expression did not significantly
correlate with grade of DCIS (Additional file 5: Figure S4),
but was significantly associated with IDC tumor grade
(Figure 2A). Furthermore, CXCL1 RNA expression was
significantly associated with high grade tumors (Figure 2B).Table 2 Relationship between known prognostic factors
and CXCL1 protein expression in breast cancer stroma
Factor r 95% CI p-value n
Age 0.12 -0.03 to 0.40 0.08 79
tumor size 0.18 -0.11 to 0.44 0.19 51
BCL2 -0.06 -0.40 to 0.29 0.72 34
P53 0.08 -0.23 to 0.38 0.60 43
Ki67 0.25 -0.07 to 0.51 0.12 41
ER -0.07 -0.37 to 0.24 0.70 42
PR 0.10 -0.22 to 0.40 0.51 42
HER2 0.14 -0.19 to 0.44 0.40 40
EGFR 0.07 -0.26 to 0.39 0.63 38
No. of lymph node metastases 0.17 -0.14 to 0.45 0.28 23
Association between CXCL1 protein expression and commonly used
prognostic markers was determined in DCIS and IDC stromal tissues using
Spearman Correlation analysis. Significance was determined by p<0.05.
r= correlation coefficient.There was no significant association with age or tumor
size (Table 3). In summary, these data indicate a statistically
significant association between stromal CXCL1 expression
and tumor grade.
Patient samples used for immunohistochemistry analysis
were collected within the last 4 years, and did not include
outcome data. However, we were able to analyze for
associations between stromal CXCL1 RNA levels and
tumor recurrence and poor survival in Oncomine
using the Finak database. We quantified the number
of recurrence-free patients that were negative or positive
for CXCL1 expression. A total of 10/53 or 19% of patients
experienced tumor recurrence, consistent with 5 year
follow-up studies showing that 11 to 19.3% of patients
with IDC experience disease recurrence [59,60]. The
percentage of recurrence-free patients in the CXCL1
positive group significantly decreased over time, from
1 to 5 years (Figure 3A). We analyzed the cohort of patient
samples, in which tumor recurrence was measured after
5 years of treatment, and found a significant correlation
between increased CXCL1 RNA expression in breast
cancer stroma and increased tumor recurrence (Figure 3B).
These data indicate a significant association between
stromal CXCL1 RNA expression and disease recurrence.
To determine whether the increased tumor recurrence was
related to changes in patient survival, we analyzed the
patient cohort for relationships between stromal CXCL1
RNA and survival. Patients with a poor survival outcome
Figure 2 Stromal CXCL1 expression is associated with tumor
grade. A. Stromal CXCL1 protein expression was analyzed for
association with tumor grade of IDC by Kruskall-Wallis tests, followed
by Dunn’s post-hoc comparison. B. CXCL1 RNA expression values
were analyzed for association with tumor grade. Statistical analyses were
performed using Wilcoxon Two-Sample Tests. Statistical significance was
determined by p <0.05. *p ≤0.001 ***p ≥0.05. Values expressed
as Mean ± SEM.
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http://www.biomedcentral.com/1471-2407/14/781showed significantly higher levels of expression (Figure 3C).
In summary, these data that increased CXCL1 expression
is associated with increased recurrence and decreased
survival.
Elevated expression of CXCL1 in stromal derived
fibroblasts is associated with decreased TGF-β signaling
CXCL1 has been shown to be induced in fibroblasts by
melanoma cells [61]. Breast CAFs were also positive forTable 3 Relationship between known prognostic factors
and CXCL1 RNA expression in breast cancer stroma
Prognostic factor r 95% CI p-value
Age -0.13 -0.41 to 0.17 0.38
Tumor size -0.004 -0.31 to 0.30 0.97
Associations were determined using Spearman Correlation analysis of data
obtained from the Finak microarray database. Significance determined
by p<0.05.
r= correlation coefficient. N=53.CXCL1 RNA expression [45]. These studies indicate that
cancer associated fibroblasts are a potential source of
CXCL1 expression. Fibroblasts in breast cancer stroma
show non-overlapping expression of α- SMA and FSP1,
indicating the presence of different subsets of fibroblasts
[32]. To determine whether CXCL1 was expressed in par-
ticular fibroblast subsets in breast cancer, we performed
co-immunofluorescence staining for CXCL1 expression
with α-SMA or FSP1. Expression of CXCL1 was positive
in the tumor epithelium and stroma, consistent with DAB
expression patterns. We observed that CXCL1 overlapped
with both α-SMA and FSP1 expressing cells (Figure 4).
Some α-SMA and FSP1 positive cells did not express
CXCL1, possibly reflecting differences in gene expression
activity of these fibroblasts. In summary, these data
indicate CXCL1 is expressed in both α-SMA and FSP1
positive fibroblasts in breast cancer stroma.
We observed stromal CXCL1 expression was independent
of many known prognostic factors (Table 2), and that
CXCL1 expression was localized to CAFs. Therefore, we
analyzed for molecular factors affecting CXCL1 expression
in fibroblasts. Transforming Growth Factor Beta (TGF-β)
signaling modulates cell proliferation and induces produc-
tion of growth factors, angiogenic factors, extracellular
matrix proteins and proteases in fibroblasts. These
processes are vital for mammary ductal branching and
morphogenesis during mammary gland development [62].
As an important regulator of fibroblast activity, the TGF-β
pathway was a strong candidate. Therefore, we compared
the protein expression patterns of stromal CXCL1
with TGF-β, and expression of phosphorylated SMAD2
and phosphorylated SMAD3, key downstream effector
proteins [62,63]. Decreased expression of TGF-β, phos-
phorylated SMAD2 and phosphorylated SMAD3 proteins
were observed in DCIS and IDC stromal tissues, compared
to normal stroma (Figure 5). Positive expression of stromal
CXCL1 was inversely correlated with expression of TGF-β,
phosphorylated SMAD2 and phosphorylated SMAD3
proteins (Table 4). These data indicate an inverse correlation
between stromal CXCL1 protein expression and expression
of TGF-β related proteins. We also analyzed the RNA
expression patterns of CXCL1 and TGF-β related genes
including TGFB1, TGFBR2, SMAD2 and SMAD3. By
Spearman correlation analysis, no significant associations
were detected between stromal CXCL1 RNA expression
and expression of TGFB1, SMAD3 or TGFBR2 genes.
CXCL1 expression positively correlated with SMAD2 gene
expression (Table 5). In summary, these data indicate
a negative correlation between stromal CXCL1 protein
expression and expression of TGF-β signaling components,
and a positive correlation between RNA expression of
CXCL1 and SMAD2.
We performed further studies to clarify the role of
TGF-β signaling on CXCL1 expression in fibroblasts. In
Figure 3 Increased CXCL1 RNA expression in breast cancer stroma is associated with poor prognosis. CXCL1 RNA expression values
were obtained from the Finak microarray database, and analyzed for the following. A. The percentage of patients negative or positive for CXCL1
expression exhibiting tumor recurrence over time. The fractions below the graph depict recurrence-free patients over the total number of CXL1
negative or CXCL1 positive patients. B. Associations with overall tumor recurrence after 5 years. C. Associations with decreased survival after
5 years. Statistical analysis was performed using the Log-rank Test (A) or Wilcoxon Two-Sample Test (B and C). Mean ± SD. Statistical significance
was determined by p <0.05. *p ≤0.001, ***p≥0.05.
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http://www.biomedcentral.com/1471-2407/14/781previous studies, we had generated a conditional
knockout mouse model (FspKO), in which exon 2 of
the Tgfbr2 gene was deleted by cre, placed under the
control of the Fsp1 promoter. Mammary fibroblasts
isolated from FspKO mice and control mice (Flox/Flox)
were isolated and immortalized. Immortalized fibroblasts
were shown to be genetically stable and behave similarly
to primary fibroblasts in vitro and when transplanted into
mice [49]. These studies demonstrate a reliable model to
study the role of TGF-β signaling on CXCL1 expression in
mammary fibroblasts. By ELISA, a significant increase
in CXCL1 protein secretion was detected in FspKO fibro-
blasts, compared to control fibroblasts (Figure 6A). The
increased protein secretion corresponded to elevated
luciferase activity of the CXCL1 promoter in FspKO
fibroblasts (Figure 6B). To determine whether CXCL1
expression levels in FspKO fibroblasts were representative
of chemokine expression in CAFs, we analyzed for
CXCL1 expression in mammary fibroblasts isolated
from MMTV-PyVmT transgenic mice. CXCL1 expression
was significantly higher in CAF cell lines compared to
normal fibroblasts, and corresponded to lower levels of
TGF-β expression in CAFs (Figures 6C-D). Furthermore,
treatment of TGF-β inhibited CXCL1 secretion in thefibroblast cell lines (Figure 6E). These data demonstrate
that TGF-β signaling negatively regulates expression of
CXCL1 in CAFs.
Discussion
Empirical studies in animal models and human tissues
have established the importance of stromal fibroblasts
on cancer progression [15,64]. However, the concept of
the “tumor promoting” fibroblast has not been clearly
defined. While recent studies have shown that the
CXCL1 chemokine is expressed in tumor epithelial cells
and stromal cells, the relevance of stromal CXCL1 expres-
sion has remained poorly understood. Here we report that
elevated CXCL1 expression in breast cancer stroma is
associated with tumor recurrence and decreased patient
survival. We also show that CXCL1 is localized to α-SMA
and FSP1 expressing fibroblasts, and is negatively regulated
by TGF-β signaling. These studies contribute to the
definition of the tumor promoting fibroblast, identify
similarities and differences in CXCL1 RNA and protein
expression patterns, and demonstrate a clinical significance
for CXCL1 expression in cancer stroma.
In order to overcome the challenges of collecting suffi-
cient numbers of tissue samples, we used both commercial
Figure 4 CXCL1 co-localizes with α-SMA and FSP1 positive stroma. Patient samples of breast ductal carcinoma were co-immunofluorescence
stained for expression of CXCL1 (green) and α-SMA or FSP1 (red). Representative samples of CXCL1, α-SMA and FSP1 are shown. Sections were
counterstained with DAPI. Secondary antibody only controls are shown: anti-goat-alexa-488 for CXCL1, anti-mouse-alexa-568 for α-SMA and
anti-rabbit-alexa-568 for FSP1. Arrows and inset point to positive staining in fibroblastic cells. Scale bar =100 microns.
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http://www.biomedcentral.com/1471-2407/14/781and institutional resources. These resources allowed us to
collect the tissues needed to perform the immunohisto-
chemistry staining and quantify the level of protein expres-
sion in the breast cancer stroma. One limitation to the
immunohistochemistry analysis was that we were unable
to determine an association between stromal CXCL1
protein expression and clinical outcome, due to lack
of follow-up data from either sources. While we did
not observe significant associations between stromal
CXCL1 expression and age or ethnicity, we were unable to
determine associations between stromal CXCL1 and other
risk factors such as genetics, life-style or family history
[65,66]. The Finak microarray dataset provided new data
demonstrating a clinical relevance for RNA expression of
CXCL1 in the stroma. However, one limitation was that we
were unable to determine the association between stromalCXCL1 RNA expression and prognostic factors such as
biomarker expression or lymph node status, as these data
were not provided with the Finak dataset. In addition, we
were unable to determine an exact relationship between
stromal CXCL1 RNA and protein expression, as these
samples were not matched. To overcome these limitations,
it would be of interest in the future to conduct studies
using a sample size population with more complete clinical
profiles that would enable us to match CXCL1 RNA
expression with protein expression.
In our studies, we observed important similarities
between stromal CXCL1 protein and RNA expression
levels in breast stromal tissues. Intensity of RNA and
protein expression levels was higher in breast tumors
than in normal breast tissues. In particular, elevated
expression levels of stromal CXCL1 RNA and protein
Figure 5 Expression patterns of CXCL1 and TGF-β signaling proteins in breast cancer stroma. Adjacent sections of normal breast (n=54)
and invasive breast carcinoma (n=57) on TMAs were subject to immunohistochemistry staining for TGF-β, phosphorylated SMAD2 and phosphorylated
SMAD3 proteins. Magnified insets show representative staining in fibroblastic cells. Expression was quantified by Image J, arbitrary units. Scale bar =50
microns. Statistical analysis was performed using Kruskall-Wallis tests, followed by Dunn’s post-hoc comparison. Statistical significance was determined
by p <0.05. *p ≤0.001, **p ≤0.05. Values are expressed as Mean ± SEM.
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http://www.biomedcentral.com/1471-2407/14/781were detected in high grade tumors, and there were
no significant differences in association with the other
prognostic factors examined. We also observed several
differences in RNA and protein expression of CXCL1
in the breast stroma. Stromal CXCL1 protein expression
was positively expressed in all tumors examined, while the
RNA was expressed in a small subset of breast tumor sam-
ples. While stromal CXCL1 protein expression correlated
with tumor grade, significant levels of stromal CXCL1 RNA
expression was observed only in high grade tumors. In
addition, the stromal CXCL1 protein expression inversely
correlated with expression of TGF-β, phospho-SMAD3 and
phospho-SMAD2. In contrast, CXCL1 RNA levels positively
correlated with SMAD2 gene expression. These differences
in expression patterns for stromal CXCL1 are consistent
with previous studies showing significant variations between
RNA and protein levels observed in endometrial, colorectal
and bladder carcinomas [67].Table 4 Protein expression of TGF-β signaling components
inversely correlate with CXCL1 expression in breast stroma
Signaling component r 95% CI p-value n
TGF-β -0.33 -0.52 to -0.09 0.01 69
p-Smad2 -0.25 -0.44 to -0.027 0.02 80
p-Smad3 -0.32 -0.50 to -0.10 <0.01 81
Spearman Correlation used to determine the association between expression
of CXCL1 and expression of TGF-β signaling components in normal and breast
cancer stroma. Normal stroma refers to samples from both reduction
mammoplasty and adjacent breast tissue.
Significance was determined by p<0.05. r= correlation coefficient.Multiple factors could account for differences in
CXCL1 protein and RNA expression. RNA and protein
expression data were from unmatched samples, and
the heterogeneity of breast cancer patients could have
contributed to differences in RNA and protein expression
levels. It is also possible that post-transcriptional and
post-translational mechanisms contribute to the differences
in CXCL1 RNA and protein expression in breast cancer
stroma in lower grade tumors. Studies have shown that
NF-κB, PARP (poly ADP ribose polymerase) and CREB
(cAMP Response Element Binding) proteins positively
regulate CXCL1 transcription, while CAAT displacement
proteins negatively regulate CXCL1 transcription. Their
activities have been reported in breast cancer and could
affect CXCL1 transcript levels [68,69]. Post-transcriptional
mechanisms active in breast cancer include microRNA
activity [70]. Mir-7641 has been shown to regulate CXCL1Table 5 Correlations between RNA expression of CXCL1
and gene expression of TGF-β signaling components
Signaling component r 95% CI p-value
TGFB1 0.19 -0.09 to 0.45 0.18
TGFBR2 0.12 -0.16 to 0.39 0.12
SMAD2 0.33 0.06 to 0.57 0.01
SMAD3 0.11 -0.17 to 0.38 0.42
Association between CXCL1 protein expression and expression of TGF-β
signaling components was determined using Spearman Correlation analysis
of IDC stroma and normal adjacent stroma.
Significance determined by p<0.05. r= correlation coefficient.
Figure 6 CXCL1 expression is inversely associated with TGF-β signaling in mammary fibroblasts. A. Conditioned medium from Flox/Flox
or FspKO fibroblasts were analyzed for CXCL1 secretion by ELISA. B. Flox/Flox control or FspKO fibroblasts were co-transfected with CXCL1 firefly
and Renilla luciferase reporter constructs and analyzed for luciferase activity. Values are normalized to Renilla. C.-D. Conditioned medium from
carcinoma associated fibroblast cell lines (41CAF, 83CAF) or normal fibroblasts (NAF) were analyzed by ELISA for CXCL1 (C) or TGF-β secretion
(D). E. Fibroblasts were treated with 5 ng/ml TGF-β for 48 hours and analyzed for CXCL1 secretion by ELISA. Statistical analysis was determined
by two-tailed Student t-tests. Statistical significance was determined by p <0.05. *p ≤0.001, **p <0.05. Values are expressed as Mean ± SEM. Experiments
were conducted in triplicate with three replicate samples per group.
Zou et al. BMC Cancer 2014, 14:781 Page 12 of 16
http://www.biomedcentral.com/1471-2407/14/781expression in endothelial cells [71]. Mir200 has been shown
to modulate CXCL1 mRNA expression in invasive breast
cancers [72]. It is possible that microRNA levels in breast
tumor tissues may affect CXCL1 RNA levels. Possible post-
translational mechanisms for CXCL1 involve biochemical
binding between CXCL1 and heparin in the extracellular
matrix to enhance CXCL1 protein half-life [73]. Thus, it is
possible for stromal CXCL1 protein expression levels to be
higher than RNA levels, as observed in breast cancer
stroma.
Our studies indicate that CXCL1 is elevated in breast
CAFs, and is associated with increased tumor recurrence
and tumor grade. As the binding receptors CXCR1
and CXCR2 are expressed on myeloid derived cells and
carcinoma cells [74,75], CXCL1 expression in CAFs may
serve to regulate paracrine signaling interactions with
immune cells and cancer cells to promote chemo-resistance
and tumor progression. This hypothesis is supported
by previous studies on CXCL1 expression in the MMTV-
PyVmT transgenic mouse model, where CXCL1 func-
tioned to recruit myeloid immune suppressor cells thatenhanced survival and invasion of mammary tumors.
Treatment of mammary tumors with Doxorubicin re-
sulted in the selection of drug resistant mammary carcin-
oma cells with elevated CXCL1 expression in cancer cells
[54]. Studies have shown that chemotherapies do not
efficiently target CAFs for cell death but rather enhance
the tumor promoting activities of fibroblasts by promoting
secretion of growth factors and cytokines [24,25]. It is
possible that CXCL1 expression in CAFs is retained or
further elevated after chemotherapy treatment, serving to
promote the survival and selection of chemo-resistant
tumor cells. It would be of interest to conduct further
studies on stromal CXCL1 expression on breast tumor
tissues from patients treated with chemotherapies, and
conduct functional studies in animal models. These
studies would clarify the role of CAF-derived CXCL1 on
breast cancer progression and tumor recurrence.
Our studies introduce new findings that elevated CXCL1
expression in breast cancer stroma inversely correlate with
expression of TGF-β signaling components. Furthermore,
we find that TGF-β suppresses CXCL1 expression in
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http://www.biomedcentral.com/1471-2407/14/781cultured CAFs. These studies indicate that CAFs decrease
TGF-β signaling to enhance breast cancer progression,
partly by increasing CXCL1 chemokine expression.
These observations are consistent with previous studies
demonstrating a tumor suppressive role for TGF-β
signaling in the breast stroma. Transgenic mice expressing
dominant negative TGF-β type II receptor in mammary
stroma exhibited mammary hyperplasia [76]. Cre
mediated deletion of exon 2 of TGF-β type II receptor
gene (Tgfbr2) in mammary fibroblasts (FspKO) inhibited
TGF-β mediated suppression of fibroblast proliferation.
Co-transplantation of FspKO fibroblasts with 4 T1 and
PyVmT mammary carcinoma cells in the subrenal
capsule of nude mice enhanced tumor progression.
These tumor promoting phenotypes were associated
increased expression of growth factors and receptor
tyrosine kinases [49,77,78]. It is possible that increased
CXCL1 expression would act in concert with increased
growth factor expression to enhance invasiveness of breast
carcinomas.
We and others observed expression of TGF-β and
phosphorylated Smad proteins in cancer cells indicating
active TGF-β signaling. As TGF-β is expressed in the
epithelium and could signal to fibroblasts in a paracrine
manner [79-82], it is unclear how TGF-β signaling
would be down-regulated in the stroma. As fibroblasts
are more genetically stable than cancer cells [83], it is
possible that mechanisms other than genetic mutations
would down-regulate TGF-β signaling in CAFs. Stat3,
MAPK and NF-κB inhibit TGF-β signaling in cells [84,85],
and may contribute to decreased TGF-β expression
and phosphorylated SMAD2 or SMAD3 expression
in breast CAFs. It is also possible that epigenetic
mechanisms, such as methylation of TGFB and SMAD
promoters [86,87] would silence gene expression and
down-regulate TGF-β signaling in breast cancer
stroma. It would be of interest to further study how
TGF-β signaling is regulated in the context of breast
stromal tissues, in order to better understand how
CAFs are regulated.
Conclusions
In summary, we provide insight into the clinical signifi-
cance of stromal derived CXCL1 expression, and show that
α-SMA and FSP1 positive CAFs in breast cancer stroma
are sources of CXCL1 expression. In addition, we also
demonstrate that the TGF-β signaling pathway is an
important negative regulator CXCL1 expression in
breast CAFs. As CXCL1 is increasingly shown to play
important roles in tumor recurrence and chemoresistance,
further studies on the impact of CXCL1 expression
on the breast tumor microenvironment will aid in the
development of novel anti-cancer therapies to combat
drug resistant tumors.Additional files
Additional file 1: Figure S1. Expression of stromal CXCL1 in DCIS
subtypes. DCIS patient specimens were immunostained for CXCL1
protein expression and quantified for expression in the stroma among
the different classified subtypes. Subtypes are organized in descending
order of diagnosis. Statistical analysis among groups was performed
using the Kruskall-Wallis test followed by Dunn’s post-hoc comparison.
Statistical significance was determined by p <0.05. ***p ≥0.05, in comparison
with all groups. Values are expressed as Mean ± SEM.
Additional file 2: Figure S2. Expression of stromal CXCL1 in IDC
subtypes. IDC patient specimens were immunostained for CXCL1 and
quantified for expression in the stroma among the different classified
subtypes. Subtypes are organized in descending order of diagnosis.
Statistical analysis among groups was performed using the Kruskall-Wallis
test followed by Dunn’s post-hoc comparison. Statistical significance was
determined by p <0.05. NOS = Not Otherwise Specified. ***p ≥0.05, in
comparison with all groups. Values are expressed as Mean ± SEM.
Additional file 3: Table S1. Relationship between age and CXCL1
expression in breast cancer stroma. The association between age and
stromal CXCL1 protein expression was determined in the US Biomax and
BCRF datasets by Spearman Correlation analysis. Significance determined
by p < 0.05. r = correlation coefficient.
Additional file 4: Figure S3. Expression of stromal CXCL1 in individual
datasets. Levels of stromal CXCL1 were compared between the US Biomax
and BCRF datasets. Statistical analysis among groups was performed using
the Kruskall-Wallis test followed by Dunn’s post-hoc comparison. Statistical
significance was determined by p <0.05. ***p ≥0.05, in comparison with all
groups. Mean ± SEM is shown for each group.
Additional file 5: Figure S4. Stromal CXCL1 expression is not
associated with grade of DCIS. DCIS patient specimens were immunostained
for CXCL1 protein expression and analyzed for association with histologic
grade. n =2 for DCIS grade 1, n =7 for DCIS grade 2 and n =13 for DCIS grade
3. Statistical analysis among groups was performed using the Kruskall-Wallis
test. Statistical significance was determined by p <0.05. ***p ≥0.05, in
comparison with all groups. Values are expressed as Mean ± SEM.
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